Search

Now showing items 1-9 of 9

Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis

Bardhan K.D.; Van Rensburg C. (2001)

Background: Several clinical trials have shown that pantoprazole (40 mg) and omeprazole (40 or 20 mg) have similar efficacy and safety in the treatment of grade II-IV reflux oesophagitis (Savary-Miller classification). ...

Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias

Schwartz P.J.; Priori S.G.; Spazzolini C.; Moss A.J.; Michael Vincent G.; Napolitano C.; Denjoy I.; Guicheney P.; Breithardt G.; Keating M.T.; Towbin J.A.; Beggs A.H.; Brink P.; Wilde A.A.M.; Toivonen L.; Zareba W.; Robinson J.L.; Timothy K.W.; Corfield V.; Wattanasirichaigoon D.; Corbett C.; Haverkamp W.; Schulze-Bahr E.; Lehmann M.H.; Schwartz K.; Coumel P.; Bloise R. (2001)

Background - The congenital long-QT syndrome (LQTS) is caused by mutations on several genes, all of which encode cardiac ion channels. The progressive understanding of the electrophysiological consequences of these mutations ...

Comparison of a new desktop spirometer (Diagnosa®) with a laboratory spirometer

Maree D.M.; Videler E.A.; Hallauer M.; Pieper C.H.; Bolliger C.T. (2001)

Background: The Diagnosa is a fully integrated system, able to determine spirometry, ECG, blood pressure and body composition. Real time data can be transferred via Internet to a remote receiving center. Objectives: The ...

The factor structure for positive and negative symptoms in South African Xhosa patients with schizophrenia

Emsley R.A.; Niehaus D.J.H.; Mbanga N.I.; Oosthuizen P.P.; Stein D.J.; Maritz J.S.; Pimstone S.N.; Hayden M.R.; Laurent C.; Deleuze J.-F.; Mallet J. (2001)

Most studies investigating the symptom dimensions of schizophrenia utilising the Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS) favour a three factor model. ...

High-dose antithrombin III in severe sepsis: A randomized controlled trial

Warren B.L.; Eid A.; Singer P.; Pillay S.S.; Carl P.; Novak I.; Chalupa P.; Atherstone A.; Penzes I.; Kubler A.; Knaub S.; Keinecke H.-O.; Heinrichs H.; Schindel F.; Juers M.; Bone R.C.; Opal S.M. (2001)

Context: Activation of the coagulation system and depletion of endogenous anticoagulants are frequently found in patients with severe sepsis and septic shock. Diffuse microthrombus formation may induce organ dysfunction ...

Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder

Montgomery S.A.; Kasper S.; Stein D.J.; Hedegaard K.B.; Lemming O.M. (2001)

Serotonin reuptake inhibitors appear to be uniquely effective treatments for obsessive-compulsive disorder (OCD). This double-blind, placebo-controlled study was the first trial to assess the efficacy of the most selective ...

Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression

Wirth M.; Tyrrell C.; Wallace M.; Delaere K.P; Sanchez-Chapado M.; Ramon J.; Hetherington J.; Pina F.; Heynes C.F; Borchers T.M; Morris T.; Stone A. (2001)

Objectives. To investigate the efficacy and tolerability of bicalutamide (Casodex) as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with localized or locally advanced (T1b-T4, ...

Reduced activation of peripheral blood neutrophils after late-phase asthmatic responses but not in mild stable asthma

Mattheyse F.J.; Van Heerden K.; Mattheyse M.; Williams Z.; Bouic P.; Van Schalkwyk E.M.; Bardin P.G. (2001)

Background: Asthma is a process of chronic allergic inflammation that may be worsened by the activation of neutrophils during acute exacerbations. Objective: We investigated our hypothesis that changes in cellular activation ...

Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder

Stein D.J.; Montgomery S.A.; Kasper S.; Tanghoj P. (2001)

Although serotonin reuptake inhibitors (SRIs) are the medications of choice in the treatment of obsessive-compulsive disorder (OCD), only 50-60% of patients respond to a single trial of any of these agents. Improved knowledge ...